Bristol-Myers Insider Trading Suit Is Compliance Gut Check

Law360, New York (August 6, 2012, 7:03 PM EDT) -- Criminal charges against a Bristol-Myers Squibb Co. executive accused of trading on nonpublic information he gleaned from working in the company's acquisitions department should serve as a cautionary tale for general counsel whose companies are in deal-making mode, experts say.

While company directors rarely are held criminally liable for employees' insider trading, they can face regulatory enforcement, shareholder lawsuits and a public relations black eye. And with the U.S. Securities & Exchange Commission cracking down on financial crimes and institutional shareholders muscling up, experts say now...
To view the full article, register now.